The clinical trial, called Transplantation In Myocardial Infarction Evaluation (TIME), was designed to see if heart function would improve by administering stem cells derived from the patient's own bone marrow either three or seven days after a heart attack

Chelsea Therapeutics International Ltd., of Charlotte, N.C., reported results from a clinical study designed to determine the blood pressure effect of escalating doses (100 mg, 200 mg and 400 mg) of Northera (droxidopa) in hypotensive individuals with chronic spinal cord injuries ranging from cervical to low thoracic lesions...The Phase IIa/b study, completed in December 2011, involved the use of a proprietary autologous stem cell formulation (Monocell) indicated for neoangiogeneses

It keeps progenitor stem cells healthy and undifferentiated, "ready and waiting, if you will, until they get the signal that the body needs red or white cells," Martino said...The net proceeds will be used for working capital and general corporate purposes, including the continued conduct of the Abili-T clinical study, Opexa's recently initiated Phase IIb trial of personalized T-cell therapy Tcelna in patients with secondary progressive multiple sclerosis.

Each will be injected with 100,000 human embryonic stem cell-derived retinal pigment epithelial cells...Study efficacy results demonstrated positive trends in slowing the rate of disease progression, ranging from 13 percent to 19 percent in multiple parameters of clinical benefit, although those pre-defined endpoints did not reach statistical significance

Bioheart Inc., of Sunrise, Fla., said it will start its ANGEL trial in Mexico and said NorthStart Biotech LLC, a consortium of Bioheart directors and shareholders, agreed to fund the study, which will test the safety and efficacy of LipiCell (adipose-derived stem cells) in congestive heart failure patients...Cellceutix Corp., of Beverly, Mass., said it has recruited the first patients with advanced solid tumors for clinical studies of cancer candidate Kevetrin

In September, AlloCure Inc., of Burlington, Mass., started a Phase II trial of AC607, its mesenchymal stem cell therapy for AKI...Puma is working on neratinib, an oral, irreversible kinase inhibitor for HER2-posistive metastatic breast cancer. (See BioWorld Today, Oct. 22, 2012.)

StemCells Inc., of Newark, Calif., said two papers reporting clinical and preclinical data demonstrating the therapeutic potential of the company's HuCNS-SC cells (purified human neural stem cells) for a range of myelination disorders were published in the Oct. 10, 2012, edition of Science Translational Medicine

The positive clinical effects of the twice-daily dose of the drug relative to placebo were observed in a variety of standard psoriasis assessment parameters, with the responses accumulating over the 24 weeks...Neuralstem Inc., of Rockville, Md., updated data from the Phase I trial to test its NSI-566 spinal cord stem cells in the treatment of amyotrophic lateral sclerosis

The trial will have two stages: The first stage will treat patients with escalating doses of SGI-100 and carboplatin to identify the maximum-tolerated dose and preliminary biological and clinical activity, while the second stage will randomize patients to receive SGI-100 plus carboplatin or one of three treatments of choice as determined by the clinical investigator – toptecan, pegylated liposomal doxorubicin or paclitaxel...Athersys Inc., of Cleveland, completed enrollment of the first patient

Data were published in the Journal of Allergy and Clinical Immunology...Neuralstem Inc., of Rockville, Md., gained the go-ahead to start a clinical trial in motor deficits due to ischemic stroke with its spinal cord stem cells (NSI-566) at BaYi Brain Hospital in Beijing, through its subsidiary, Neuralstem China (Suzhou Neuralstem Biopharmaceutical Co. Ltd

The randomized, double-blind trial, known as AETHERA, is comparing Adcetris against placebo in patients at high risk of residual Hodgkin lymphoma following autologous stem cell transplant...In 2011, the FDA gave accelerated approval to Adcetris for Hodgkin lymphoma after the failure of either autologous stem cell transplant or at least two multi-agent chemotherapy regimens in transplant-ineligible patients and for systemic anaplastic large cell lymphoma after the failure of at least one multi-agent

Gamida Cell Ltd., of Jerusalem, said it completed enrollment in a Phase I/II study of NiCord, an expanded cell graft derived from an entire unit of umbilical cord blood enriched with stem cells...Imprimis Pharmaceuticals Inc., of Solana Beach, Calif., said it started a clinical trial testing Impracor, a topical cream designed to deliver ketoprofen

The investment comes in the wake of positive clinical data from early stage trials of both CV9103 and NSCLC vaccine CV9201...CV9103 comprises four individual mRNA molecules, which encode PSA (prostate-specific antigen), PSCA (prostate stem cell antigen), PSMA (prostate-specific membrane antigen) and STEAP1 (six transmembrane epithelial antigene of the prostate 1), respectively

That subject, a 45-year-old male with acute myeloid leukemia, had suffered complications following a hematopoietic stem cell transplantation...Proceeds will be used to support clinical studies, R&D activities and for general corporate purposes, including working capital and administrative expenses

America Stem Cell Inc., of San Antonio, said it started a single-center study testing ASC-101 in dual-umbilical cord transplantation in patients with hematologic malignancies...The Phase I/II trial, which has enrolled and dosed its first patient, is designed to study the safety of ASC-101 in the hematopoietic stem cell transplant setting and gather preliminary data on potential clinical benefit

Proceeds will be used for general corporate purposes, including general working capital, capital expenditures, R&D, clinical trials, acquisitions of new technologies or businesses and investments...Neuralstem focuses on developing treatments based on human neuronal stem cells

Agenus Inc., of Lexington, Mass., said clinical data from a Phase I trial of a Prophage Series vaccine (HSPPC-96, vitespen) to treat patients with recurrent glioblastoma multiforme (GBM) were published online by Clinical Cancer Research...In a multicenter Phase II study, the compound demonstrated symptomatic relief and clinical and mycological benefits after a single administration delivered as a vaginal suppository formulation

University Hospitals Case Medical Center, in Cleveland, plans to conduct a U.S. Phase II study examining the safety and effectiveness of the adult stem cell therapy product MultiStem, developed by Athersys Inc., of Cleveland, in ischemic stroke...Data from the trial suggested clinical benefit, defined as partial response and stable disease of more than four months following up to eight cycles of treatment, with aldoxorubicin at the maximum-tolerated dose in 10 of 13 evaluable patients with relapsed

Advanced Cell Technology Inc., of Marlborough, Mass., treated its fourth patient, or the first in a second cohort, in a Phase I/II trial for dry, age-related macular degeneration with its human embryonic stem cell-derived retinal pigment epithelial cells...Spectrum Pharmaceuticals Inc., of Henderson, Nev., said data published in the Journal of Clinical Oncology showed first-line consolidation with Zevalin (ibritumomab tiuxetan) injection in patients with mantle-cell lymphoma, following initial